Clinical Trials and Research

Key Points Non-myeloablative haploidentical (NMAC-HID) transplant would be cost-effective for long-term SCD remission in adultsMaximum gene therapy price…

AbstractPurposeSickle Cell Disease (SCD) is a monogenic, autosomal recessive disorder caused by mutations in the β-globin gene, resulting in the production of…

Higher blood levels of erythropoietin (EPO), a hormone that stimulates the production of red blood cells, increase the risk of blood clot-related, or thrombotic,…

SummaryQuestionThis study analyzed the cost-effectiveness of three treatment strategies for sickle cell disease (SCD): standard care (SOC), gene therapy (GT), and…

AbstractRenin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may…

AbstractSickle cell disease (SCD) is a globally prevalent inherited hemoglobinopathy marked by chronic hemolysis, vaso-occlusion, and systemic inflammation, leading…

AbstractAlloimmunisation is a notorious dilemma in blood transfusion intervention therapy, especially in low-resource countries, and studies have shown that…

AbstractSickle cell disease (SCD) is a major global health burden, and early, accurate diagnosis is critical for effective management. Conventional diagnostic…

AbstractThe Cure Sickle Cell Initiative (CureSCi), created by the National Heart, Lung, and Blood Institute, has developed data standards to increase…

SummarySickle cell disease (SCD) is a complex thrombo-inflammatory disorder in which haemolysis, platelet activation, thrombocytosis, inflammation and endothelial…